Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib + Selenium in Recurrent Platinum-Resistant Ovarian Cancer
NCT05672095Phase 2Withdrawn
- Sponsor
- City of Hope
- Start
- Apr 2025
- Primary completion
- Nov 2026
- Modality
- Orthosteric Ligands
01
Overview
A Phase 2 trial of niraparib, selenium in ovarian carcinoma, fallopian tube carcinoma (PFTC), primary peritoneal carcinoma (PPC), sponsored by City of Hope. Planned start Apr 2025; status: withdrawn.
02
Drugs
niraparibselenium
03
Conditions
ovarian carcinomafallopian tube carcinoma (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT05672095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05672095.